Log in to search using one of your social media accounts:

 

Oncolytic Virus Succeeds in Melanoma Trial (CME/CE)
(MedPage Today) -- Add-on to ipilimumab better than drug alone (Source: MedPage Today Dermatology)
Source: MedPage Today Dermatology - October 10, 2017 Category: Dermatology Source Type: news

Adjuvant Ipilimumab in Melanoma: Future in Doubt Adjuvant Ipilimumab in Melanoma: Future in Doubt
This hugely expensive regimen has now been eclipsed by the checkpoint inhibitor nivolumab, placing the future of adjuvant ipilimumab under question, argues one expert.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 10, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Merck Hedges Bets With Keytruda Lung Study
Merck has started a big study testing whether its immunotherapy drug, Keytruda, helps newly diagnosed lung cancer patients more if it is combined with Yervoy, a drug made by rival Bristol-Myers Squibb. But don't interpret the study as a bet the combination will prove effective. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 6, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Source Type: news

First Randomized Study To Evaluate IMLYGIC ® (Talimogene Laherparepvec), An Oncolytic Viral Therapy, In Combination With A Checkpoint Inhibitor Published In The Journal Of Clinical Oncology
Results Demonstrated a Doubling of Objective Response Rate Compared to Ipilimumab Alone in Unresectable Advanced Melanoma Responses Were Not Limited to Injected Lesions and Favored the Combination Arm Across Subsets of Disease THOUSAND OAKS, Calif., Oct. 5, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Journal of Clinical Oncology has published positive results from the IMLYGIC® (talimogene laherparepvec) Phase 2 '264 study. The study met its primary endpoint of objective response rate (ORR), demonstrating that IMLYGIC in combination with YERVOY® (ipilimumab) more than doubled ORR, define...
Source: Amgen News Release - October 5, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data Nivolumab-Ipilimumab Combo for Melanoma: 3-Year Survival Data
Three-year survival rates with advanced melanoma are 52% with nivolumab and 34% with ipilimumab, but 58% with a sequential combination of the two, according to the latest results comparing the two anticancer biologics separately and together.Reuters Health Information (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 13, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adjuvant Nivolumab Tops Ipilimumab in Melanoma
Longer recurrence - free survival for stage IIIB, IIIC, IV melanoma (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - September 12, 2017 Category: Cancer & Oncology Tags: Dermatology, Oncology, Pharmacy, Conference News, Source Type: news

Clear Benefit With Adjuvant Nivolumab in Resected Melanoma Clear Benefit With Adjuvant Nivolumab in Resected Melanoma
Adjuvant nivolumab significant improves relapse-free survival and reduces toxicity in comparison with ipilimumab in stage III/IV resected melanoma for patients at risk for relapse, trial results reveal.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 12, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Study Evaluating Opdivo in Combination with Yervoy Stopped Early for Demonstrating Overall Survival Benefit
The median PFS for the combination group was 11.6 months (95% CI: 8.71 to 15.51) versus 8.4 months (95% CI: 7.0 to 10.8) for the sunitinib group.09/17/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - September 11, 2017 Category: Urology & Nephrology Source Type: news

Immunotherapy Changes First-Line Paradigm in Advanced RCC Immunotherapy Changes First-Line Paradigm in Advanced RCC
For the first time, sunitinib has been beaten in a phase 3 trial; the combination of nivolumab and ipilimumab showed a significant improvement in overall survival.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 11, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Adjuvant nivolumab superior to ipilimumab in surgically resected stage III/IV melanoma
(European Society for Medical Oncology) Adjuvant nivolumab is superior to standard of care ipilimumab in patients with surgically resected stage III/IV melanoma who are at high risk of relapse, according to late-breaking results from the CheckMate 238 trial presented today at the ESMO 2017 Congress in Madrid and published in the New England Journal of Medicine. The anti-programmed death-1 (PD-1) antibody nivolumab led to better relapse-free survival, with fewer side effects than ipilimumab. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - September 11, 2017 Category: Cancer & Oncology Source Type: news

After melanoma surgery, Bristol's Opdivo offers new care standard
MADRID (Reuters) - Bristol-Myers Squibb's immunotherapy drug Opdivo is a better and safer option than its older medicine Yervoy for treating melanoma patients who have had surgery to remove disease, researchers reported on Monday. (Source: Reuters: Health)
Source: Reuters: Health - September 10, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

BMS ’ Phase III combination trial for renal cell carcinoma meets endpoints
Bristol-Myers Squibb (BMS) has reported positive results from its Phase III clinical trial (CheckMate -214) of Opdivo and Yervoy combination for renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - September 7, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb shares slip as kidney cancer drug trial falls short of goal
...use of the drugs Opdivo and Yervoy showed that renal cell carcinoma patients responded better to the combination versus those taking the drug sunitinib, survival rates without progression of the disease did not reach statistical significance.08/16/2017 (Source: Kidney Cancer Association)
Source: Kidney Cancer Association - August 16, 2017 Category: Urology & Nephrology Source Type: news

BMS Phase III ’s combination trial for RCC meets one co-primary endpoint
Bristol-Myers Squibb (BMS) has reported top-line results from the Phase III CheckMate -214 clinical trial of Opdivo (nivolumab) and Yervoy (ipilimumab) combination to treat advanced or metastatic renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - August 15, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb announces topline results from CheckMate -214
Bristol-Myers Squibb Company (NYSE: BMY) announced topline results today from the CheckMate -214 trial investigating Opdivo (nivolumab) in combination with Yervoy (ipilimumab) versus sunitinib in intermediate and poor-risk patients previously untreated advanced or metastatic renal cell carcinoma. (Source: World Pharma News)
Source: World Pharma News - August 15, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Pembrolizumab Plus Reduced Ipilimumab Dose Active in Advanced Melanoma
Standard-dose pembrolizumab with four reduced doses of ipilimumab followed by standard-dose pembrolizumab had a manageable safety profile and antitumor activity in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - August 7, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
A new cooperative research study including Norris Cotton Cancer Center's Lionel Lewis, MB BCh, MD, finds that nivolumab plus ipilimumab therapy demonstrated manageable safety, notable antitumor activity, and durable responses with promising long term overall survival in patients with metastatic renal cell cancer (mRCC). (Source: World Pharma News)
Source: World Pharma News - July 27, 2017 Category: Pharmaceuticals Tags: Featured Research Research and Development Source Type: news

Immunotherapy Combination in Metastatic RCC Proves Effective
Patients with metastatic renal cell carcinoma had durable responses and manageable safety when treated with the combination of nivolumab and ipilimumab. (Source: CancerNetwork)
Source: CancerNetwork - July 26, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Genitourinary Cancers News Renal Cell Carcinoma Source Type: news

Drug combination shows better tolerance and effectiveness in metastatic renal cell cancer
(Dartmouth-Hitchcock Medical Center) A novel combination of nivolumab plus ipilimumab for patients with metastatic kidney cancer is proving to be a more effective treatment with more durable tumor response than the two immunotherapies used separately. The promising combination therapy demonstrated manageable safety, notable antitumor activity, and durable responses with better long term overall survival in patients with metastatic renal cell cancer. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - July 26, 2017 Category: International Medicine & Public Health Source Type: news

FDA Approves Ipilimumab for Pediatric Melanoma
The FDA has expanded the approval of ipilimumab (Yervoy) to include the treatment of pediatric melanoma patients 12 years and older with unresectable or metastatic disease. (Source: CancerNetwork)
Source: CancerNetwork - July 25, 2017 Category: Cancer & Oncology Authors: Ian Ingram Tags: Melanoma News Pediatric Cancers Source Type: news

U.S. Food and Drug Administration expands approval of Yervoy ® (ipilimumab) to include pediatric patients 12 years and older with unresectable or metastatic melanoma
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy ® (ipilimumab) injection for intravenous use to now include the treatment of unresectable or metastatic melanoma in pediatric patients 12 years of age and older. (Source: World Pharma News)
Source: World Pharma News - July 24, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

FDA Expands Approval of Yervoy (ipilimumab) to Include Pediatric Patients 12 Years and Older with Unresectable or Metastatic Melanoma
PRINCETON, N.J.--(BUSINESS WIRE) July 24, 2017 --Bristol-Myers Squibb Company (NYSE:BMY) today announced that the U.S. Food and Drug Administration (FDA) has expanded the indication for Yervoy (ipilimumab) injection for intravenous use to now... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 24, 2017 Category: Drugs & Pharmacology Source Type: news

Exelixis and BMS start Phase III combination trial for renal cell carcinoma
Exelixis and Bristol-Myers Squibb (BMS) have started the Phase III CheckMate 9ER clinical trial of Cabometyx (cabozantinib) combined with Opdivo (nivolumab) or both Opdivo and Yervoy (ipilimumab) to treat renal cell carcinoma (RCC). (Source: Drug Development Technology)
Source: Drug Development Technology - July 10, 2017 Category: Pharmaceuticals Source Type: news

SMART Protocol for Mesothelioma Adds Immunotherapy
In conclusion, we demonstrated the importance of the immune system in the benefit of clinical protocols using…radiation followed by surgery.” The post SMART Protocol for Mesothelioma Adds Immunotherapy appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - July 6, 2017 Category: Environmental Health Authors: Walter Pacheco Tags: emerging treatments for mesothelioma immunotherapy for mesothelioma SMART mesothelioma SMART protocol mesothelioma smart protocol mix with immunotherapy Source Type: news

Nivolumab Alone or With Ipilimumab Produced Durable Response in SCLC
Treatment with nivolumab alone and in combination with ipilimumab resulted in durable responses in patients with previously treated small-cell lung cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 16, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Conferences/ASCO Lung Cancer News Source Type: news

Mesothelioma Clinical Trial Opens with High Expectations
Newly diagnosed mesothelioma patients around the world have begun enrolling in a much-anticipated, phase III clinical trial involving an immunotherapy drug combination with groundbreaking potential. The trial, designed as first-line therapy for unresectable pleural mesothelioma, will measure the effectiveness of nivolumab (Opdivo) and ipilimumab (Yervoy) against standard-of-care chemotherapy. A presentation this month at the 2017 American Society of Clinical Oncology (ASCO) annual meeting sparked high expectations for the trial, detailing early, impressive effectiveness involving the two drugs in second-line and third-lin...
Source: Asbestos and Mesothelioma News - June 16, 2017 Category: Environmental Health Authors: Matt Mauney Tags: Abramson Cancer Center American Society of Clinical Oncology Bristol-Myers Squibb cancer immunotherapy research cisplatin for mesothelioma Cleveland Clinic Cancer Center CRS-207 disease control rate Dr. Arnaud Scherpereel Dr. Patrick Ma Source Type: news

Threshold Pharma begins dosing of cancer drugs evofosfamide and ipilimumab in Phase I trial
US-based biopharmaceutical firm Threshold Pharmaceuticals has begun dosing patients in a Phase I clinical trial of evofosfamide in combination with ipilimumab to treat various cancers. (Source: Drug Development Technology)
Source: Drug Development Technology - June 14, 2017 Category: Pharmaceuticals Source Type: news

Bristol-Myers Squibb announces new collaboration to evaluate combination therapy in colorectal cancer
Bristol-Myers Squibb Company (NYSE:BMY) announced today it has entered into a clinical research collaboration with Novartis to investigate the safety, tolerability and efficacy of Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in combination with Mekinist® (trametinib), as a potential treatment option for metastatic colorectal cancer in patients with microsatellite stable tumors where the tumors are proficient in mismatch repair (MSS mCRC pMMR). (Source: World Pharma News)
Source: World Pharma News - June 5, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Amgen Presents New Phase 2 Data On IMLYGIC ® (Talimogene Laherparepvec) Investigational Combination At ASCO 2017
First Randomized Study to Evaluate the Combination of IMLYGIC, an Oncolytic Viral Therapy, With a Checkpoint Inhibitor Data Demonstrate IMLYGIC in Combination With YERVOY® (Ipilimumab) Doubled Objective Response Rate in Unresectable Advanced Melanoma Responses Not Limited to Injected Lesions; 50 Percent or Higher Reduction in Visceral Lesion Size Occurred More Frequently in Patients in the Combination Arm THOUSAND OAKS, Calif., June 3, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the Phase 2 '264 study that demonstrated IMLYGIC® (talimogene laherparepvec) in combination with ...
Source: Amgen News Release - June 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Array BioPharma and BMS to assess cancer drugs in Phase I/II combination trial
Array BioPharma has entered a strategic clinical research collaboration with Bristol-Myers Squibb (BMS) to evaluate the combination of binimetinib with Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen in a Phase I/II clinical trial to trea … (Source: Drug Development Technology)
Source: Drug Development Technology - May 31, 2017 Category: Pharmaceuticals Source Type: news

Better Cancer Immunotherapy Drugs Through X-Ray Crystallography
May 30, 2017—(BRONX, NY)—Immunotherapy drugs to combat cancer have stimulated tremendous excitement among patients and physicians alike. They debuted in 2011, when the U.S. Food and Drug Administration approved ipilimumab (Yervoy) to treat metastatic melanoma, a usually fatal disease. Since then, other immunotherapies have reached the market, including pembrolizumab (Keytruda), nivolumab (Opdivo), atezolizumab (Tecentriq) and avelumab (Bavencio). (Source: Einstein News)
Source: Einstein News - May 30, 2017 Category: Universities & Medical Training Source Type: news

Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Novel combinations of binimetinib, Opdivo® (nivolumab) and Yervoy® (ipilimumab) to be studied in colorectal cancer patients BOULDER, Colo. and NEW YORK, May 30, 2017 -- (Healthcare Sales & Marketing Network) -- Array BioPharma (Nasdaq: ARRY) an... Biopharmaceuticals, Oncology Array BioPharma, Bristol-Myers Squibb, binimetinib, nivolumab, ipilimumab (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 30, 2017 Category: Pharmaceuticals Source Type: news

Array BioPharma and Bristol-Myers Squibb announce strategic collaboration
Array BioPharma (Nasdaq:ARRY) and Bristol-Myers Squibb Company (NYSE:BMY) today announced the companies have entered into a clinical research collaboration to investigate the safety, tolerability and efficacy of Array's investigational MEK inhibitor, binimetinib in combination with Bristol-Myers Squibb's Opdivo (nivolumab) and Opdivo + Yervoy (ipilimumab) regimen as a potential treatment for metastatic colorectal cancer in patients with microsatellite stable tumors. (Source: World Pharma News)
Source: World Pharma News - May 30, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Immunotherapies Show Promise in Small-Cell Lung Cancer
This video reviews immunotherapy trials in small-cell lung cancer, including studies on pembrolizumab, nivolumab monotherapy, and nivolumab in combination with ipilimumab. (Source: CancerNetwork)
Source: CancerNetwork - May 5, 2017 Category: Cancer & Oncology Authors: Gregory P. Kalemkerian, MD Tags: Videos Lung Cancer Source Type: news

Bristol-Myers beats Wall St estimates, helped by cancer drug Opdivo
NEW YORK (Reuters) - Bristol-Myers Squibb Co on Thursday reported higher-than-expected quarterly earnings, helped by increased sales of cancer drugs Opdivo and Yervoy and blood thinner Eliquis. (Source: Reuters: Health)
Source: Reuters: Health - April 27, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bavarian Nordic commences Phase II combination trial for prostate cancer
Danish-based biotechnology firm Bavarian Nordic has commenced a Phase II clinical trial of Prostvac (rilimogene) in combination with Yervoy (ipilimumab) and / or Opdivo (nivolumab) to treat localised prostate cancer patients. (Source: Drug Development Technology)
Source: Drug Development Technology - April 19, 2017 Category: Pharmaceuticals Source Type: news

CheckMate 067 Shows OS Improved With Nivolumab/Ipilimumab in Melanoma
A nivolumab/ipilimumab combination significantly improved overall survival for advanced melanoma patients. (Source: CancerNetwork)
Source: CancerNetwork - April 10, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Conferences/AACR 2017 Melanoma News Source Type: news

First Phase 3 OS Results With Melanoma ImmunoTx Combo First Phase 3 OS Results With Melanoma ImmunoTx Combo
Nivolumab, alone or in combination with ipilimumab, was better than ipilimumab monotherapy in a phase 3 trial. But there's another pressing question with this first-of-its-kind clinical trial.Medscape Medical News (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - April 7, 2017 Category: Pathology Tags: Hematology-Oncology News Source Type: news

Yervoy (Ipilimumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - April 6, 2017 Category: Drugs & Pharmacology Source Type: news

Immunotherapy Combination Promising in Advanced Melanoma
The combination of an intratumoral injection of CVA21 and ipilimumab has demonstrated durable response with minimal toxicity in patients with advanced melanoma. (Source: CancerNetwork)
Source: CancerNetwork - April 4, 2017 Category: Cancer & Oncology Authors: Leah Lawrence Tags: Melanoma News Source Type: news

For Bristol-Myers, A Victory And A Mystery
In a relief to investors, the combination of Opdivo and Yervoy extends survival in melanoma. More data being released this afternoon could yield answers to the question of why Opdivo did not show a benefit in previously untreated lung cancer. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - April 3, 2017 Category: Pharmaceuticals Authors: Matthew Herper, Forbes Staff Tags: NYSE:BMY NYSE:MRK Source Type: news

The first overall survival data from the Phase 3 CheckMate -067 clinical trial
Bristol-Myers Squibb Company (NYSE:BMY) today announced the first overall survival (OS) data from the Phase 3 CheckMate -067 clinical trial. With a minimum follow-up of 28 months, the median OS had not yet been reached in either of the two Opdivo treatment groups and was 20 months for the Yervoy monotherapy group (95% CI: 17.1-24.6). Opdivo in combination with Yervoy and as a monotherapy reduced the risk of death 45% [hazard ratio (HR) 0.55; 95% CI: 0.42-0.72; P (Source: World Pharma News)
Source: World Pharma News - April 3, 2017 Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news

Questions Over Adjuvant Ipilimumab in Melanoma Questions Over Adjuvant Ipilimumab in Melanoma
An editorial raises questions on data for patient-reported outcomes for adjuvant ipilimumab, 10 mg/kg, in melanoma; toxicity also questioned.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - February 16, 2017 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

How this cancer immunotherapy pioneer is working to improve next-gen drugs
If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies. As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells. Checkpoint inhibitors, so-called… (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 23, 2017 Category: Pharmaceuticals Authors: Ron Leuty Source Type: news

How this cancer immunotherapy pioneer is working to improve next-gen drugs
If anyone knows the knock on first-generation cancer immunotherapy drugs, it's Matthew Krummel. Now he's working with three big drug developers to improve next-generation cancer immunotherapies. As a graduate student in the 1990s at the University of California, Berkeley, Krummel helped to discover the first "checkpoint inhibitor" — eventually developed by Bristol-Myers Squibb Co. as Yervoy — that helps the immune system identify otherwise cloaked cancer cells. Checkpoint inhibitors, so-called… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - January 23, 2017 Category: Biotechnology Authors: Ron Leuty Source Type: news

Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
PRINCETON, N.J.--(Healthcare Sales & Marketing Network)--Bristol-Myers Squibb Company (BMY) announced today that it has decided not to pursue an accelerated regulatory pathway for the combination of Opdivo plus Yervoy in first-line lung cancer in the U.S. ... Biopharmaceuticals, Oncology, FDA Bristol-Myers Squibb, Opdivo, Yervoy, lung cancer (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 20, 2017 Category: Pharmaceuticals Source Type: news

Bristol won't seek faster Opdivo/Yervoy lung cancer approval
(Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for a combination of its two immunotherapy drugs as an initial treatment for lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - January 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news

Bristol won't seek faster Opdivo, Yervoy lung cancer drug approvals
(Reuters) - Bristol-Myers Squibb Co on Thursday said it has decided not to seek accelerated U.S. approval for its combination of two immunotherapy drugs as an initial treatment for lung cancer. (Source: Reuters: Health)
Source: Reuters: Health - January 20, 2017 Category: Consumer Health News Tags: healthNews Source Type: news